Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
Holding PYXS?
Track your performance easily
PYXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.39 - $6.85
Previous CloseN/A
Volume258.73K
Average Volume (3M)825.13K
Market Cap
$95.15M
Enterprise Value$97.07M
Total Cash (Recent Filing)$19.69M
Total Debt (Recent Filing)$6.00K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Mar 20, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding59,465,730
10 Day Avg. Volume672,262
30 Day Avg. Volume825,126
Standard Deviation0.32
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.89
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue5.81
Enterprise Value/Gross Profit53.93
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$9.60Price Target Upside519.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Pyxis Oncology News
PremiumCompany Announcements
Pyxis Oncology Reports Promising Phase 1 Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical DevelopmentPositive initial data with strongest efficacy seen in head and neck squamous cell carcinoma, demonstrating a robust clinical potential for PYX-201.
Collaborative EffortsA newly announced collaboration with Merck to test PYX-201 in combination with Keytruda highlights strategic partnerships aimed at enhancing treatment efficacy.
Financial StabilityPyxis Oncology's financial position is strong, with approximately $146 million in cash, providing a secure runway to support operations well into the future.
Bears Say
Clinical DevelopmentPyxis Oncology announced that it is halting the clinical development of PYX-106, which has been viewed as risky due to a prior failure of similar treatments by other companies.
Market SentimentThe short interest in Pyxis Oncology's stock is relatively high at 15.1% of the float.
Stock PerformanceUpon the release of these preliminary data, PYXS declined 41% in after-hours stock trading.
---
Ownership Overview
10.74% Insiders
6.65% Mutual Funds
23.90% Other Institutional Investors
50.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $1.39 and its highest was $6.85 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $95.15M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Mar 20, 2025 which is in 49 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Nov 12, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.318 by -$0.032.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.32.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 59,465,730 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.318. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Among the largest hedge funds holding Pyxis Oncology’s share is Perceptive Advisors LLC. It holds Pyxis Oncology’s shares valued at 2M.
---
Pyxis Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.60 (519.35% Upside)
$9.60 (519.35% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 508.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $174.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.04%
12-Months-Change
Fundamentals
Return on Equity
-39.34%
Trailing 12-Months
Asset Growth
4.62%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
---
PYXS Stock 12 Month Forecast
Average Price Target
$9.60
▲(519.35% Upside)
Technical Analysis
Fate Therapeutics
―
Kala Pharmaceuticals
―
Cabaletta Bio
―
Nurix Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering PYXS
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+4.78%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +4.78% per trade.
---